HSBC downgraded Novo Nordisk (NVO) to Hold from Buy with a DKK 300 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk falls -8.7%
- Prothena price target raised to $8 from $4 at BofA
- Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress
- Morning Movers: Novo Nordisk sinks after Alzheimer’s disease study results
- Novo Nordisk Stock (NVO) Plunges After Alzheimer’s Drug Trial Misses Key Goal